Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Parathyroid hormone (Natpara) is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
• The total number of studies reviewed was 5, all of which were systematic reviews or meta-analyses.
• Patients on standard treatments with calcium and vitamin D report significantly lower quality of life compared to normal populations, suggesting a potential need for additional treatments like Natpara.
• Continuous PTH infusion via pumps has been found effective and safe for patients who do not respond well to standard therapy, indicating that Natpara might provide a superior alternative for such refractory cases.
• There is no significant difference in serum calcium levels between PTH therapies (e.g., Natpara) and control groups; however, there may be reduced urinary calcium without increased serious adverse events when using PTH therapy.
• Current literature lacks robust evidence on the optimal management of post-thyroidectomy hypoparathyroidism, implying that further research into therapies like Natpara could benefit inadequately treated patient subgroups.